PROCEPT BioRobotics (NASDAQ:PRCT) Director Antal Rohit Desai Buys 98,699 Shares

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai acquired 98,699 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $24.55 per share, for a total transaction of $2,423,060.45. Following the acquisition, the director directly owned 426,262 shares of the company’s stock, valued at $10,464,732.10. The trade was a 30.13% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Antal Rohit Desai also recently made the following trade(s):

• On Friday, March 6th, Antal Rohit Desai bought 160,317 shares of PROCEPT BioRobotics stock. The stock was acquired at an average cost of $23.59 per share, with a total value of $3,781,878.03.
• On Thursday, March 5th, Antal Rohit Desai purchased 167,246 shares of PROCEPT BioRobotics stock. The shares were acquired at an average price of $25.58 per share, for a total transaction of $4,278,152.68.

PROCEPT BioRobotics Trading Up 4.3%

Shares of NASDAQ:PRCT opened at $25.26 on Tuesday. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $1.42 billion, a PE ratio of -14.77 and a beta of 1.03. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The firm has a fifty day moving average price of $29.11 and a 200 day moving average price of $32.83.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.PROCEPT BioRobotics’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) EPS. Analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds have recently modified their holdings of the stock. Vega Investment Solutions lifted its position in shares of PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares during the period. JTC Employer Solutions Trustee Ltd bought a new stake in PROCEPT BioRobotics in the third quarter valued at $30,000. Caitong International Asset Management Co. Ltd raised its stake in PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics during the fourth quarter worth $40,000. Finally, US Bancorp DE lifted its holdings in shares of PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after acquiring an additional 1,079 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

Analyst Ratings Changes

Several research firms recently issued reports on PRCT. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Wells Fargo & Company dropped their target price on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a report on Thursday, February 26th. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Jefferies Financial Group downgraded PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 26th. Finally, Leerink Partners dropped their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of “Hold” and an average target price of $40.82.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.